Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-FR Version v7-EN
Language French English
Date Updated 2020-01-24 2020-01-24
Drug Identification Number 02453908 02453908
Brand name ACT BUPRENORPHINE/NALOXONE ACT BUPRENORPHINE/NALOXONE
Common or Proper name ACT-BUPREN/NALOX TAB ACT-BUPREN/NALOX TAB
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients BUPRENORPHINE NALOXONE BUPRENORPHINE NALOXONE
Strength(s) 2MG 0.5MG 2MG 0.5MG
Dosage form(s) TABLET TABLET
Route of administration SUBLINGUAL SUBLINGUAL
Packaging size 30 30
ATC code N07BC N07BC
ATC description DRUGS USED IN ADDICTIVE DISORDERS DRUGS USED IN ADDICTIVE DISORDERS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2019-10-02 2019-10-02
Estimated end date 2020-01-31 2020-01-31
Actual end date 2020-01-23 2020-01-23
Shortage status Resolved Resolved
Company comments
Health Canada comments